Il monitoraggio della terapia nel paziente con sclerosi multipla
DOI:
https://doi.org/10.19156/abtpn.2015.0008Keywords:
Multiple sclerosis, Therapy monitoring, Taylored therapy, Subcutaneous therapyAbstract
No abstract available (Neurology)
Similar Articles
- Mario Crisci, Anticoagulant therapy in a patient with a history of cerebral hemorrhage , AboutOpen: Vol. 4 No. 1 (2018): January - December 2018
- Valeria Dealessi, Giovanni Gigante, Claudia Leporati, Ugo G. Viora, Psoriasis at the time of COVID-19: results of an Italian survey on patients and caregivers , AboutOpen: Vol. 9 No. 1 (2022): January-December 2022
- Federico Guerra, Interaction between chemotherapeutics and anticoagulants , AboutOpen: Vol. 4 No. 1 (2018): January - December 2018
- Anna Corsi, Roberto Trevisan, Renal insufficiency and linagliptin therapy: a case report , AboutOpen: Vol. 4 No. 1 (2018): January - December 2018
- Vera Frison, Alessio Filippi, Natalino Simioni, Patient not adequately controlled with insulin therapy and hospitalized for congestive heart failure , AboutOpen: Vol. 4 No. 1 (2018): January - December 2018
- Maria Grazia Frigo, Major obstetric hemorrhage management , AboutOpen: Vol. 9 No. 1 (2022): January-December 2022
- Julia Menichetti, Guendalina Graffigna, Giuliana Pitacco, Darinka Daneu, Lorella Bucci, Marta Baldo, A co-constructed implementation path of active involvement practices in a context of integrated care: the experience of a participatory research with the ASUGI of Trieste , AboutOpen: Vol. 7 No. 1 (2020): January - December 2020
- Paolo Simioni, Classical and Point-of-Care tests in severe hemorrhage management , AboutOpen: Vol. 9 No. 1 (2022): January-December 2022
- Tea Zeppola, Efficacy of second-line treatment with capecitabine and lapatinib in HER2-positive mammary neoplasia, with encephalic metastasis, after first-line therapy with dual anti-HER2 block , AboutOpen: Vol. 4 No. 1 (2018): January - December 2018
- Francesca Fiorentino, Beatrice Canali, Paolo Morelli, Federica Demma, Brentuximab vedotin in combination with doxorubicin, vinblastine and dacarbazine for first-line treatment of stage IV HL: cost impact on subsequent lines in Italy , AboutOpen: Vol. 10 No. 1 (2023): January-December 2023
<< < 5 6 7 8 9 10 11 12 13 > >>
You may also start an advanced similarity search for this article.
